Latest Articles
Cryotherapy For Abdominal Wall Endometriosis - François Cornelis, MD - Endometriosis Foundation of America - The Blossom
Cryotherapy For Abdominal Wall Endometriosis - François Cornelis, MD Endometriosis Foundation of America - The Blossom
Published: May 2, 2024, 7 a.m.
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate - Frontiers
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate Frontiers
Published: April 29, 2024, 7 a.m.
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer - Cancer Health Treatment News
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer Cancer Health Treatment News
Published: April 9, 2024, 7 a.m.
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response - Nature.com
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response Nature.com
Published: April 2, 2024, 7 a.m.
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post
Published: March 27, 2024, 6:45 p.m.
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network
Published: March 21, 2024, 7 a.m.
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer - Oncology News Central
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer Oncology News Central
Published: March 20, 2024, 7 a.m.
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain - FiercePharma
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain FiercePharma
Published: March 18, 2024, 7 a.m.
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers - Cancer Therapy Advisor
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers Cancer Therapy Advisor
Published: March 17, 2024, 7 a.m.
Comparative efficacy of different growth hormone supplementation protocols in improving clinical outcomes in women with poor ovarian response undergoing assisted reproductive therapy: a network meta-analysis - Nature.com
Comparative efficacy of different growth hormone supplementation protocols in improving clinical outcomes in women with poor ovarian response undergoing assisted reproductive therapy: a network meta-analysis Nature.com
Published: Feb. 9, 2024, 8 a.m.
Link copied to clipboard!